Glaukos GKOS US — Capital Expenditure
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Glaukos in its filing.
Tagged under the XBRL concept gkos:CapitalExpenditure.
The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Glaukos's us — capital expenditure.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Glaukos's US — capital expenditure?
- Glaukos (GKOS) reported US — capital expenditure of $3.84M in Q1 2026.
- How has Glaukos's US — capital expenditure changed year-over-year?
- Glaukos's US — capital expenditure increased by 101.3% year-over-year, from $1.91M to $3.84M.
- What is the long-term trend for Glaukos's US — capital expenditure?
- Over 4 years (2021 to 2025), Glaukos's US — capital expenditure has grown at a -36.9% compound annual growth rate (CAGR), from $47.71M to $7.57M.
- What does US — capital expenditure mean?
- The amount of cash spent on purchasing or maintaining physical assets in the United States.
- How do you interpret US — capital expenditure?
- Higher spending typically signals investment in future growth or capacity expansion, while lower spending may indicate a focus on cash preservation or a mature asset cycle.
- How does US — capital expenditure compare across companies?
- Standard metric for assessing reinvestment rates; peers in the medical device sector vary significantly based on their manufacturing strategy (in-house vs. outsourced).